About
Contact & Profiles
A5029342111
Research Areas
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Esophageal and GI Pathology
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
Jiangsu Cancer Hospital
2024
Nanjing Medical University
2024
Background. Based on PACIFIC trial, durvalumab as consolidation therapy following concurrent chemoradiotherapy (cCRT) has been a new standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). In clinical applications, there are heterogeneous adjustments or novel strategies specialized discussions in experienced multidisciplinary teams. This study retrospectively compared the efficacy and safety of different first-line treatments NSCLC. Methods. We analyzed 397 patients...
10.1155/2024/8585035
article
EN
cc-by
International Journal of Clinical Practice
2024-02-12
10.1016/j.ijrobp.2022.07.1050
article
EN
International Journal of Radiation Oncology*Biology*Physics
2022-10-22
Coming Soon ...